# HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

> **NCT06849492** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Triple Negative Breast Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** SKB264
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06849492
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849492, "HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06849492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*